Through its banking and finance and capital markets offerings, Liedekerke is a key contact among financial institutions, corporates, and private equity players. Banking practice head Freya Mareels leads on leveraged and corporate finance, real estate finance, and asset-based lending. Thomas Vanthournout demonstrates a strong track record in acquisition finance matters. The capital markets team, headed by Wim Dedecker, handles IPOs and secondary issues, as well as a range of debt transactions including bond issues, securitisations and accelerated bookbuilds.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

‘Liedekerke offers comprehensive advice in the field of banking, finance and capital markets, offering clients both technical precision and commercially minded solutions.'
‘Freya Mareels stands out for combining sharp technical expertise in banking and finance with a pragmatic, solution-oriented approach.'
‘Wim Dedecker - pragmatic, good follow up.’
‘Freya Mareels: I would not hesitate to instruct Freya again. She had excellent technical knowledge and was able to explain issues clearly to us.'
‘Excellent work, very precise and pragmatic at the same time. Very pleasant to work with and seamless processes which makes things very efficient.’
‘Freya Mareels is excellent, her work is flawless and if discussions intensify or problem arise, she always finds solutions.’

Key clients

Siparex
IDI SCA
ING Belgium
Belfius Bank
BNP Paribas Fortis
Fronnt Group
Odontolia Group
Macquarie Bank Europe DAC
MUFG Bank
Balta Industries NV
Fortress Investment Group
Lloyds Bank PLC

Work highlights

Advises Siparex on unitranche financing provided by Eurazeo Private Debt for its investment in WVT Industries and Roam Technology.

Assisted IDI SCA with the €83m financing, by way of a syndicated senior facilities agreement with ING Belgium and Belfius Bank, of the acquisition of the Intersoft Electronics group from Waterland Private Equity.

Advised Fortress Investment Group, the reference shareholder of Celyad Oncology SA, in connection with a private placement of 3,333,333 newly issued shares by Celyad, fully subscribed by Fortress.